Nano-X Imaging Ltd.(NNOX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,828 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
NNOX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Nano-X Imaging Ltd. (NNOX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NNOX at 17.1/100 on a 32-signal composite quality model, placing it at rank #2,828 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Nano-X Imaging Ltd. reports quarterly revenue of $13.0M, net income of $-75.0M, free cash flow of $-45.0M. Top institutional holders of NNOX by reported 13-F value include UBS Group AG, ARK Investment Management, MARSHALL WACE, LLP, based on the most recent SEC filings. NNOX trades on the Nasdaq exchange and files with the SEC under CIK 1795251. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NNOX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nano-X Imaging Ltd. directly from SEC EDGAR. Nano-X Imaging Ltd.'s 13F Pro composite quality score has ranged between 17 and 21 since 2026, currently 17.1 — a declining long-term trajectory across 19 quarterly and live scoring snapshots.
Revenue
FY 2025
$13.0M
Net Income
FY 2025
$-75.0M
Free Cash Flow
FY 2025
$-45.0M
ROIC
FY 2025
-54.8%
D/E Ratio
FY 2025
0.02
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+15.4% YoYNet Income
-40.2% YoYOperating Income
-37.9% YoYEPS (Diluted)
-27.5% YoYTotal Assets
-22.8% YoYTotal Debt
-48.8% YoYOp. Cash Flow
-11.5% YoYFree Cash Flow
-14.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.0M +15.4% | $11.3M +13.9% | $9.9M +15.5% | $8.6M +557.8% | $1.3M | — |
| Net Income | $-75.0M -40.2% | $-53.5M +11.9% | $-60.8M +46.3% | $-113.2M -83.2% | $-61.8M -41.0% | $-43.8M |
| Operating Income | $-78.2M -37.9% | $-56.7M +9.3% | $-62.6M +46.8% | $-117.7M -91.2% | $-61.6M -40.1% | $-43.9M |
| EPS (Diluted) | $-1.16 -27.5% | $-0.91 +15.7% | $-1.08 +50.2% | $-2.17 -69.5% | $-1.28 -4.1% | $-1.23 |
| Total Assets | $162.2M -22.8% | $210.0M -4.0% | $218.6M -13.9% | $253.9M -30.1% | $363.2M +53.8% | $236.1M |
| Total Debt | $3.1M -48.8% | $6.1M +75.4% | $3.5M +0.3% | $3.5M +2300.7% | $145.0K | — |
| Operating Cash Flow | $-40.8M -11.5% | $-36.6M +18.3% | $-44.8M -3.2% | $-43.4M -14.0% | $-38.1M -76.1% | $-21.6M |
| Free Cash Flow | $-45.0M -14.3% | $-39.4M +18.1% | $-48.1M +4.9% | $-50.6M +17.4% | $-61.2M -72.2% | $-35.5M |
Get alerted when NNOX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nano-X Imaging Ltd. including:
Top Institutional Holders of NNOX
UBS Group AG
$1.7M1,477,524 shARK Investment Management LLC
$935.7K806,614 shMARSHALL WACE, LLP
$903.0K778,417 shMORGAN STANLEY
$759.6K654,808 shBlackRock, Inc.
$691.4K596,033 shAQR CAPITAL MANAGEMENT LLC
$650.3K560,599 shBANK OF AMERICA CORP /DE/
$529.9K456,777 shGOLDMAN SACHS GROUP INC
$404.3K348,573 shHRT FINANCIAL LP
$383.0K330,195 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$377.4K325,312 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $1.7M | 1,477,524 |
| ARK Investment Management LLC | $935.7K | 806,614 |
| MARSHALL WACE, LLP | $903.0K | 778,417 |
| MORGAN STANLEY | $759.6K | 654,808 |
| BlackRock, Inc. | $691.4K | 596,033 |
| AQR CAPITAL MANAGEMENT LLC | $650.3K | 560,599 |
| BANK OF AMERICA CORP /DE/ | $529.9K | 456,777 |
| GOLDMAN SACHS GROUP INC | $404.3K | 348,573 |
| HRT FINANCIAL LP | $383.0K | 330,195 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $377.4K | 325,312 |
Companies Similar to NNOX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ADC Therapeutics SA
Centessa Pharmaceuticals plc
Canopy Growth Corp
Karyopharm Therapeutics Inc.
TREACE MEDICAL CONCEPTS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NNOX on your watchlist
Track score changes the day Nano-X Imaging Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NNOX a good stock to buy?
13F Pro's AI-powered analysis of Nano-X Imaging Ltd. (NNOX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NNOX are available on the NNOX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NNOX is classified as a small company.
Which hedge funds own NNOX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NNOX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nano-X Imaging Ltd.'s investment landscape.